PharmacoEconomics & Outcomes News 679 - 1 Jun 2013 Vaccines pay their way in the US Routine childhood and adolescent vaccination in the US results in substantial cost savings as shown by an economic evaluation from the Centres of Disease Control and Prevention. Researchers evaluated the economic impact of 12 routine vaccinations (from the 2009 immunisation schedule) using decision analysis of a hypothetical birth cohort of 4 261 494 infants over their lifetime from both a direct cost and societal perspective. Published vaccine efficacy was used and costs included vaccine cost, administration, adverse events and parent travel and lost work time. The analysis showed approximately 44 000 deaths and 20 million cases of disease would be prevented with net savings of $US13 billion in direct costs and $68 billion in total societal costs. The direct and societal benefit-cost ratios for the immunisation programme were 2.7 and 9.2, respectively. Zhou F, et al. Economic Evaluation of the Routine Childhood and Adolescent Immunization Program in the United States, 2009. 2013 Annual Meeting of the Pediatric Academic Societies : abstr. 4335.1, 13 May 2013. 803087115 1 PharmacoEconomics & Outcomes News 1 Jun 2013 No. 679 1173-5503/10/0679-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Vaccines pay their way in the US

Download PDF Report

Upload
elisabeth
View
213
Download
1

Embed Size (px)

Citation preview

Page 1: Vaccines pay their way in the US

PharmacoEconomics & Outcomes News 679 - 1 Jun 2013

Vaccines pay their way in the USRoutine childhood and adolescent vaccination in the

US results in substantial cost savings as shown by aneconomic evaluation from the Centres of DiseaseControl and Prevention.

Researchers evaluated the economic impact of12 routine vaccinations (from the 2009 immunisationschedule) using decision analysis of a hypothetical birthcohort of 4 261 494 infants over their lifetime from botha direct cost and societal perspective. Published vaccineefficacy was used and costs included vaccine cost,administration, adverse events and parent travel and lostwork time.

The analysis showed approximately 44 000 deathsand 20 million cases of disease would be prevented withnet savings of $US13 billion in direct costs and$68 billion in total societal costs. The direct and societalbenefit-cost ratios for the immunisation programmewere 2.7 and 9.2, respectively.Zhou F, et al. Economic Evaluation of the Routine Childhood and AdolescentImmunization Program in the United States, 2009. 2013 Annual Meeting of thePediatric Academic Societies : abstr. 4335.1, 13 May 2013. 803087115